Even without input from the Oncology Care Model, community practices can measure performance data through a robust electronic medical record like Flatiron, said Erich Mounce, chief operating officer, OneOncology.
Even without input from the OCM, community practices can measure performance data through a robust electronic medical record like Flatiron, said Erich Mounce, chief operating officer, OneOncology.
Transcript
For community practices not involved in models like the OCM [Oncology Care Model], is it difficult to measure practice performance? What are the best ways to do this?
I don’t know if it’s difficult, I think they can do it. From my perspective they need to invest in a really robust electronic medical record, Flatiron would be a perfect example of that, and make sure they’re getting data from all of their clinical measurements, as well as, the revenue cycle measurements—I think those are really important pieces. Whether you’re an OCM or not, you can still measure your staging data, you can still measure your MIPs [merit-based incentive payment system] data, you can still measure your patient satisfaction data. I think that you should measure how you’re adhering to your own care pathways or your own regimens. Those are all things that allow you to measure your performance on a clinical basis, but also from a financial performance basis. So, absolutely you can do it. The real issue is, are you able to have enough data to really cycle through a process that is statistically relevant, number 1, and 2 is investing to get that data sometimes is really expensive. So, for group practices, they don’t want to become IT companies or data companies—I really think they need to come back full circle to your first question [of] what do I get out of a partnership, how do I survive—and that partnership I think is really important to get those kinds of things.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More